Cordlife GroupCLIFF 41 ROC (Joel Greenblatt) % is -36.96% as of Mar. 2026. GuruFocus rates CLIFF with a GF Score™ of 41/100 and a GF Value™ of $0.17 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 67.3% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cordlife Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -36.96%.
The historical rank and industry rank for Cordlife Group's ROC (Joel Greenblatt) % or its related term are showing as below:
CLIFF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -72.97 Med: 21.36 Max: 372.35
Current: -59.2
During the past 13 years, Cordlife Group's highest ROC (Joel Greenblatt) % was 372.35%. The lowest was -72.97%. And the median was 21.36%.
CLIFF's ROC (Joel Greenblatt) % is ranked worse than 67.3% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs CLIFF: -59.20
Cordlife Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Cordlife Group (OTCPK:CLIFF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Cordlife Group ROC (Joel Greenblatt) % Related Terms
Cordlife Group ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cordlife Group's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLIFF vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Cordlife Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cordlife Group's ROC (Joel Greenblatt) % falls into.
Cordlife Group ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -36.96% mean?
Cordlife Group (CLIFF) has a ROC (Joel Greenblatt) % of -36.96% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #142 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 67.3%.
Is Cordlife Group's ROC (Joel Greenblatt) % too high?
Cordlife Group's current ROC (Joel Greenblatt) % is -36.96%. Based on the distribution chart, Cordlife Group ranks #142 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cordlife Group has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #142 out of 211 companies for ROC (Joel Greenblatt) %. This places Cordlife Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cordlife Group and its competitors. Cordlife Group's current ROC (Joel Greenblatt) % is -36.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.17, compared to a current price of $0.15 — trading 11.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is -36.96%. Cordlife Group's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current ROC (Joel Greenblatt) % is -36.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of $0.15 is trading 11.5% below its estimated GF Value™ of $0.17.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
ROC (Joel Greenblatt) %: -36.96%
GF Value™: $0.17 vs. price of $0.15 (11.5% below fair value)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
41GF Score
Get the complete analysis for CLIFF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
